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Abstract
The accurate execution of DNA replication requires a strict
control of the replication licensing factors hCdt1 and hCdc6.
The role of these key replication molecules in carcinogenesis
has not been clarified. To examine how early during cancer
development deregulation of these factors occurs, we inves-
tigated their status in epithelial lesions covering progressive
stages of hyperplasia, dysplasia, and full malignancy, mostly
from the same patients. Abnormal accumulation of both
proteins occurred early from the stage of dysplasia. A frequent
cause of unregulated hCdc6 and hCdt1 expression was gene
amplification, suggesting that these components can play a
role per se in cancer development. Overexpression of hCdt1
and hCdc6 promoted rereplication and generated a DNA
damage response, which activated the antitumor barriers of
senescence and apoptosis. Generating an inducible hCdt1
cellular system, we observed that continuous stimulus by dere-
gulated hCdt1 led to abrogation of the antitumor barriers and
resulted in the selection of clones with more aggressive pro-
perties. In addition, stable expression of hCdc6 and hCdt1 in
premalignant papilloma cells led to transformation of the
cells that produced tumors upon injection into nude mice
depicting the oncogenic potential of their deregulation. [Cancer
Res 2007;67(22):10899–909]
Introduction
Genomic stability is of primary importance for survival and
proper functioning of all cells. The most deleterious type of DNA
damage leading to genomic instability is the double-strand break
(DSB; ref. 1). When DSBs occur, the DNA damage response (DDR)
pathway is activated to eliminate the genomic threat (1). The DSB-
DDR cascade consists of sensor proteins such as the Mre11/Rad50/
Nbs1 complex and 53BP1, adaptor proteins including BRCA1 and
MDC1/NFBD1, the apical signaling kinases ataxia-telangiectasia
mutated (ATM) and DNA-protein kinase, and the effector kinase
Chk2 (1). The main biochemical end effect of the DSB-DDR cascade
is p53 activation (1). The outcome of the response may be either
repair of damage (1), arrest in the form of accelerated senescence
(2), or in case of extensive damage, apoptosis (1). We recently
showed that DDR is an early inducible barrier in carcinogenesis
alarmed due to compromised DNA replication (2–4).
Disruption of normal replication mechanism, a condition termed
replication stress, can create a cellular environment prone to geno-
mic instability. Thus, accurate execution of DNA replication is
of paramount importance in maintaining genomic integrity.
The process of DNA replication relies on the control of cyclin-
dependent kinases, which regulate the molecules comprising the
replication complexes (5). Two key proteins of the replication
complex, the DNA replication licensing factors (RLF) hCdt1 and
hCdc6, when recruited during G1-S transition on the origin
recognition complexes, facilitate the loading of the minichromo-
some maintenance proteins 2 to 7 on the chromatin, thereby
licensing the origins to fire once per cell cycle (6). Deregulation of
hCdc6 and/or hCdt1 may lead to origin nonfiring or refiring,
resulting in DNA underreplication or overreplication. The ability
of deregulated RLF overexpression to cause rereplication, as
reported by Vaziri et al. (7), providing seeds for genomic instability,
has been recently challenged (8). Lately, we observed that over-
expression of hCdc6, among other factors, can cause replication
stress that evokes DDR-mediated senescence (2). High levels of
RLFs have been observed in various types of cancer (9–14); how-
ever, the issue of how early during cancer development deregula-
tion of the RLFs takes place remains unresolved.
To answer the latter question, we investigated the status of both
RLFs in human epithelial lesions covering the whole histopa-
thologic spectrum of carcinogenesis and subsequently explored
the ability of hCdc6 and/or hCdt1 to promote rereplication and
induce genomic instability and tumor aggressiveness.
Materials and Methods
Tissue samples. Frozen and formalin-fixed, paraffin-embedded material
from 75 non–small cell lung carcinomas and adjacent normal lung
tissue, and corresponding precancerous lesions were used (3, 9). Ninety-
six cases of nonfamilial colon lesions and 15 head-and-neck cases
comprising normal, hyperplastic, dysplastic, and carcinoma counterparts
(15) were randomly selected from the tissue banks of the Department of
Histology-Embryology, Athens, Greece, and four institutes from Denmark
and Norway, after local ethical committee approvals. Samples are presented
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in Supplementary Table S1. None of the patients had undergone any cancer
therapy before surgical resection of the lesions.
Cell lines. BJ, MCF7, HeLa, U2OS, and P1 cell lines were used. Cells were
maintained in DMEM (Biochrome), with 10% FCS (Biochrome), 2 mmol/L
L-Glutamine (Biochrome), and 100 Ag/mL penicillin and streptomycin
(Biochrome), respectively, at 37jC and 5% CO2.
Plasmid construction. pBabeHyg-hCdc6 was constructed by digest-
ing pCS3-hCdc6 (16) with BamHI and XhoI and subcloning hCdc6-cDNA
into pBabeHyg. hCdt1-cDNA was isolated from pCDEBD-hCdt1 (17) with
XbaI and HindIII digestions and subcloned into pCB6. The later was
digested with EcoRI to isolate the hCdt1-cDNA with ends compatible for
subcloning into pBIB and pIRES2neo vectors, respectively. Finally, the
pTRE2hyg-hCdt1 construct was obtained after excision of the hCdt1-cDNA
from pIRES2neo, using ClaI and NotI digestions, and religation into
pTRE2hyg.
Retrovirus construction and infections. BJ and U2OS cells were
transiently transduced with hCdc6 or hCdt1 and the corresponding control
vectors using the Phoenix helper-free retrovirus producer cell line, as
previously described (2).
U2OS-TetON-hCdt1 inducible system. U2OS-TetON cells (Clontech)
were transfected with pTRE2hyg-hCdt1 at f80% confluence, using
LipofectAMINE 2000 (Invitrogen). Hygromycin selection (200 mg/mL) was
initiated 4 days later and clones emerged after 2 weeks. Expression of hCdt1
in stably transfected clones was confirmed with immunoblot and reverse
transcription-PCR (RT-PCR) analysis.
Growth curve analysis. U2OS-TetON-hCdt1 cells, in the absence or
presence of doxycycline, were seeded at day 0 on 60-mm Petri dishes at a
density of 3  105. Every 3 days up to day 30, cells were trypsinized and
counted, and 3  105 cells were reseeded. The ratio of cells counted versus
the cells seeded was estimated at every subculture, and the total cell
number was calculated by multiplying these ratios with the number of cells
seeded initially.
Small interfering RNA transfection. U2OS-TetON-hCdt1 small inter-
fering RNA (siRNA) transfection was done as per previous publication (2).
Immunohistochemistry and indirect immunofluorescence analysis.
Immunohistochemistry and immunofluorescence analysis have been
previously described (2, 4, 9, 18).
Antibodies. Primary antibodies for immunohistochemistry, immunoflu-
orescence, and immunoblot analysis have been previously described (2, 3, 9,
13, 18, 19).
5-Bromo-2-deoxyuridine staining. Staining with 5-bromo-2-deoxyur-
idine (BrdUrd) was done as previously described (2).
Terminal deoxyribonucleotide transferase–mediated nick-end la-
beling assay. Double-stranded DNA breaks were detected by terminal
deoxyribonucleotide transferase–mediated nick-end labeling (TUNEL),
according to protocols described elsewhere (9).
Chromogenic and fluorescent in situ hybridization. Chromogenic
in situ hybridization (CISH) analysis was done with the Zymed SPoT-Light
HER2 CISH kit (Invitrogen) on formalin-fixed, paraffin-embedded tissue
sections, following the manufacturer’s instructions. Control reactions and
evaluation were done according to the manufacturer’s guidelines.
Senescence-associated B-galactosidase staining. Senescence-associ-
ated h-galactosidase (SA-h-gal) staining and evaluation was done as prev-
iously described (2).
Flow cytometry (fluorescence-activated cell sorting). Cells were
harvested with trypsinization and centrifuged at 1,000 rpm for 5 min at
room temperature. The pellet was resuspended in 500 AL PBS, fixed with
80% ethanol, vortexed, and stained with propidium iodide (50 Ag/mL),
in the presence of 5 mmol/L MgCl2 and 10 Ag/mL RNase A in 10 mmol/L
Tris-HCl (pH 7.5). DNA content was analyzed on a FACSCalibur (Becton
Dickinson) using the Modfit software.
Ploidy analysis. Ploidy analysis was done as previously described (18).
Protein extraction and immunoblotting. Total protein and histone
extraction from frozen tissue samples was done according to protocols
described elsewhere (3).
Nucleic acid extraction and cDNA preparation. Tissue microdissec-
tion and DNA extraction were done according to protocols described
elsewhere (20). RNA and cDNA preparation have been previously described
(20).
Differential PCR. hCdc6/hCdt1 gene amplification was assessed by the
differential PCR method, as previously used (20). Neoplastic samples
scoring z2-fold difference from the corresponding normal counterpart were
characterized as hCdt1 and/or hCdc6 gene-amplified cases and were also
confirmed by real-time PCR (MJ-Research DNA-Engine-Opticon). Primers
and annealing temperatures are given in Supplementary Table S2.
Comparative RT-PCR and real-time RT-PCR. Evaluation of hCdt1 and
hCdc6 mRNA status was done by a semiquantitative RT-PCR method
previously described (20). Two reference genes, GAPDH and PBGD , were
used to validate the results. Neoplastic samples scoring z2-fold hCdt1 and/
or hCdc6 increased expression from the corresponding normal counterpart
were characterized as overexpressed and where verified by real-time PCR
(MJ-Research DNA-Engine-Opticon; data not shown). Primers and anneal-
ing temperatures are given in Supplementary Table S2.
Pulsed-field gel electrophoresis. U2OS cells (1  106) were inserted
into 1% w/v low-melting-agarose plugs (Sigma) and incubated in 0.5 mol/L
EDTA, 1% N-laurylsarcosyl and 1 mg/mL proteinase K at 50jC for 48 h.
Plugs were washed four times in TE (10 mmol/L and 1 mmol/L) buffer and
the DNA was separated in 1% agarose (Invitrogen), 0.5  Tris-borate EDTA
(TBE: 45 mmol/L Tris-borate, 1 mmol/L EDTA) by pulsed-field gel
electrophoresis, using a CHEF DRIII apparatus and a Mini Chiller model
1000 with a variable speed pump (Bio-Rad). Electrophoresis was conducted
in 0.5 TBE at 14jC, 4 V/cm, with a fixed angle of 120j, with a switching
time 240 s for 18 h. Gels were stained for 30 min with ethidium bromide and
assessed under UV light.
Comparative genomic hybridization. Comparative genomic hybrid-
ization (CGH) was done as previously described (3).
Single nucleotide polymorphism oligonucleotide microarray anal-
ysis. U2OS cell line is highly aneuploid and hypertriploid (21). DNA was
extracted from induced and noninduced cultures at 0, 17, and 30 days.
All samples were assayed using the Mapping 250K Sty Assay Kit.9 The assay
was done according to the manufacturer’s protocol. Detection of copy
number changes was done with Chromosome Copy Number Analysis Tool
version 4.0, 9 using pairwise comparisons of test (17 days induced/
noninduced and 30 days induced/noninduced) and reference data (0 days)
and default settings. Output data comprised smoothed log 2 ratio values,
median log 2 ratio values of all contiguous single nucleotide polymorphisms
(SNP) in the given HMM copy number state segment, and the HMM copy
number state.
Invasion assay. The cellular invasion potential was estimated with a cell
invasion assay kit (Chemicon), following the manufacturer’s instructions.
Tumorigenicity assay. P1-hCdt1, P1-hCdc6, and corresponding mock
counterparts were harvested, washed in PBS, and s.c. injected (1  106 cells)
at two sites in the abdominal region of male severe combined
immunodeficient (SCID) mice. Tumor growth was measured twice to
thrice weekly. Tumorigenicity for each cell type was tested in five animals,
respectively.
Statistical analysis. Statistical analysis was done with SPSS 12.0
software.
Results and Discussion
Deregulated overexpression of the RLFs, hCdt1 and hCdc6,
is an early event in carcinogenesis. Recently, we showed that
hCdt1 and hCdc6 are overexpressed in a significant proportion
of lung carcinomas (9). To determine at what stage during
carcinogenesis deregulation of the RLFs hCdc6 and hCdt1 occurs,
we did an immunohistochemical analysis in precancerous lesions
(hyperplasias and dysplasias) located adjacent to the lung
carcinomas (3; Supplementary Table S1). Their location suggested
that they were precursors of the malignancy developed in the
9 http://www.affymetrix.com
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patients. Similar analysis was done in precancerous and cancerous
lesions from the larynx and colon (Supplementary Table S1). The
laryngeal premalignant and malignant specimens were from the
same patient, whereas the colon lesions were not.
A clear nuclear hCdct1 and/or hCdc6 signal was evident from
the stage of dysplasia in all three types of cancer studied (Fig. 1;
Supplementary Table S1). In cases stained positive for RLFs,
immunoexpression extended always from the dysplastic area to
the adjacent cancerous region and was never restricted to the
cancerous area. No signal was observed in the normal epithelium
or adjacent hyperplastic lesions of the lung and larynx. In normal
colon, hCdt1 was present in the nuclei of a limited number of cells,
located in the proliferative compartment of the crypt, as previously
shown (14), whereas hCdc6 was not detectable. In lung and
laryngeal lesions, the percentage of positive cells increased from
dysplasias to carcinomas (Fig. 1A and B). In colon, expression was
elevated from grade 1 adenomas to grade 3, whereas in the
carcinomas their immunohistochemical status was slightly reduced
(Fig. 1C). Interestingly, a subcellular shift was observed in the
staining of hCdc6 from the nuclei, mainly in dysplasias, to the
cytoplasm in carcinomas (Fig. 1A and C). Physiologically, hCdc6,
after taking part in the replication licensing process, has been
suggested to translocate to the cytoplasm for degradation (22).
The cytoplasmic expression of hCdc6 has been previously observed
in lung (9, 10) and cervical carcinomas (11) and probably repre-
sents aberrant accumulation of the protein (9) due to S-phase
deregulation.
The absence of signal in the hyperplasias and normal tissues
could mean that the levels of both factors were below the threshold
of immunohistochemical identification. In our previous study,
we showed that hCdc6 immunopositivity was restricted to cases
that exhibited markedly increased levels (>4-fold) of the protein,
as assessed by immunoblotting (9). To explore whether the absence
of staining was due to levels below the immunohistochemical
threshold, we examined the expression of hCdt1 and/or hCdc6 , by
RT-PCR, in five cases with positive immunohistochemistry signal
for both factors in the dysplastic and cancerous areas (Supple-
mentary Fig. S1A). The cases comprised lesions covering the whole
histopathologic spectrum of alterations. The RT-PCR method was
chosen because immunoblotting requires significant amount of
tissue, which is difficult to retrieve from such small lesions. The
results showed an increase of f2-fold for both hCdc6 and hCdt1
mRNA levels in the hyperplasias compared with the adjacent
normal tissue (Supplementary Fig. S1A), which justifies, according
to our previous observation (9), the absence of immunohistochem-
ical signal. On the other hand, the hCdt1 and hCdc6 levels in the
adjacent dysplastic and cancerous area increased abruptly (>5-fold;
Supplementary Fig. S1A).
Given the hCdt1 and hCdc6 role in replication, one could argue
that increased immunodetection from dysplasia to cancer could
merely reflect an increase in proliferation rate. However, no
correlation was found with the proliferation marker Ki-67 (data not
shown), confirming previous observations in carcinomas (9, 10, 12).
Moreover, the preferential staining in certain lesions (dysplasias
and cancer) and not in normally proliferating tissues or even
hyperplasias suggests that immunohistochemical detection depicts
abnormal overexpression of the proteins.
Thus, our results suggest that in very early precursor lesions
(hyperplasias), the moderate increase of hCdt1 and hCdc6
(Supplementary Fig. S1A) possibly reflects a deranged/accelerated
cell turnover, owed to local mitotic overload, leading to a poten-
tially reversible disruption of tissue homeostasis (3), whereas in
advanced lesions (dysplasia and cancer) their significant over-
abundance (Fig. 1; Supplementary Fig. S1) probably results either
from deregulation of transcription factors controlling their ex-
pression or from abrupt genomic changes, such as gene ampli-
fication.
Gene amplification is a frequent cause of deregulated hCdt1
and hCdc6 overexpression. The pivotal transcriptional activators
of hCdt1 and hCdc6 are the E2F members E2F-1 and E2F-2 (23).
Overexpression of E2F-1 and E2F-2 has been observed in various
epithelial malignancies (23). Therefore, hCdt1 and hCdc6 tran-
scriptional deregulation, due to deranged E2F expression, could be
a source of their abnormal overproduction (24). Nonetheless, there
are no reports examining whether gene amplification could
constitute an alternative mechanism of deregulated overexpres-
sion. To this end, we did a differential PCR assay in our lung cancer
data base, previously analyzed for hCdt1 and hCdc6 expression (9).
We found a 2.5- to 4.5-fold gene amplification of hCdc6 in 18 of
38 hCdc6-overexpressing cases (47%), whereas no amplification
was observed in the specimens showing normal hCdc6 levels
(Fig. 2A and B). Similarly, a 2.5- to 4-fold amplification of hCdt1
was seen in 9 of 32 samples overexpressing hCdt1 (28%), whereas
there was no hCdt1 amplification in the hCdt1 normally expressing
cases (Fig. 2A and B). Both findings were confirmed by real-time
PCR (Supplementary Fig. S1B). Concomitant amplification of both
genes was noticed in six cases (19%).
Given that hCdc6 is located in the proximity of c-erbB2 on
17q21.3 , which is frequently amplified in human cancer, we set to
examine whether hCdc6 gene amplification is a secondary event to
c-erb2 gene amplification. Therefore, we did a c-erb2 CISH in the
cases, which showed hCdc6 gene amplification with differential
PCR. Interestingly, CISH showed polysomy of chromosome 17 in
57% of these cases, whereas in the remaining samples c-erb2 gene
amplification was not noticed (Fig. 2C). The last result was also
confirmed by differential PCR, as well (Fig. 2C). Notably, polysomy
of chromosome 17 is observed in HeLa cells, which display high
expression levels of hCdc6 (Fig. 2C).
To analyze in detail the genomic profile of tumors with gene
amplification, we did a high-resolution CGH analysis in the six
specimens that exhibited gene amplification for both genes. CGH
showed amplification of the broader chromosomal region encoding
hCdc6 in two of the examined specimens (Fig. 2D), suggesting that
besides hCdc6 and c-erb2 other putative oncogenes may lay in this
area. On the other, CGH revealed some intriguing findings
regarding hCdt1 . The 16q13-24.1/2 region was found deleted in
three samples, whereas 16q24.3 , which lies in the vicinity of this
area and contains hCdt1 , was always spared (Fig. 2D). The 16q
chromosomal arm is frequently lost in many tumor types as it
contains a tumor-suppressor gene cluster proximal to the fragile
site FRA16D (25). These findings indicate that hCdt1is likely
essential for cancer cells. The lack of correlation between CGH and
differential PCR with respect to hCdt1 is possibly due to the
limitation of the particular method to detect genomic changes
affecting less than a few megabases (26).
Altogether, the above findings suggest that hCdc6 amplification
can be a primary discrete event during carcinogenesis, and that
gene amplification represents a frequent cause of hCdc6 and hCdt1
unregulated overexpression, at least in one tumor type.
Deregulated hCdt1 and hCdc6 overexpression generates
DSBs activating the DDR checkpoint. Gene amplification is a
hallmark of tumor cells and genes undergoing amplification are
Deregulation of hCdt1 and hCdc6 in Carcinogenesis
www.aacrjournals.org 10901 Cancer Res 2007; 67: (22). November 15, 2007
considered as candidate oncogenes. Whether hCdt1 or hCdc6
overexpression can act in an oncogenic manner endowing the
cells with capacity to promote carcinogenesis is unclear. Studies
examining the transformation potency of hCdt1 are controversial
(24). We recently showed that expression of hCdc6 in diploid
fibroblasts activates the DNA damage checkpoint inducing a
senescence phenotype (2), supporting its oncogenic role. Here,
we show a similar phenomenon for hCdt1, after introducing it in BJ
Figure 1. hCdt1 and hCdc6 overexpression is an early event during carcinogenesis. Immunohistochemical analysis of hCdc6 and hCdt1 in normal, hyperplastic,
dysplastic, and cancerous lesions of the lung (A), larynx (B ), and colon (C ). Columns, mean of the percentages of cells staining positive for hCdc6 and hCdt1
in the aforementioned lesions; bars, SD. Red arrows, in grade 1 colonic adenoma, immunopositivity for hCdt1. N, normal tissue; H, hyperplastic tissue; D, dysplastic
tissue; GI, grade 1 and 2 adenoma (mild to moderate dysplasia, representing low grade dysplasia, LGD ); GIII, grade 3 adenoma (severe dysplasia, representing
high grade dysplasia, HGD ); T, tumor tissue.
Cancer Research
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normal diploid fibroblasts by retroviral infection (Supplementary
Fig. S2A).
However, experiments in primary cells cannot clearly define the
role of hCdt1 and hCdc6 overexpression in tumorigenesis because,
as presented earlier, the shift from regulated to deregulated RLF
overexpression occurs later between the stage of dysplasia and the
onset of cancer. Defining the time point of a particular molecular
alteration is of great importance in understanding its role in the
natural history of each tumor type. It has been suggested that
aberrant overexpression of RLFs could favor cancer progression
by promoting genetic instability via rereplication (7). Nevertheless,
the ability of hCdt1 to induce rereplication and generate DSBs
was questioned recently (8). To clarify this issue and examine the
potential of the RLFs to induce genomic instability, we introduced
hCdt1 and hCdc6 into the U2OS human osteosarcoma cell line.
We favored these cells because their genetic background (p53
intact, pRb hyperphosphorylated, and p16INK4A lost; ref. 19)
resembles the genetic profile of high-grade dysplastic-early cancer
lesions seen in many types of cancer such as those of the
respiratory track (27, 28). Thus, the events following introduction
of hCdt1/hCdc6 would simulate closer the in vivo observations.
In addition, the U2OS is a low endogenous DDR activity cellular
system (29), thus facilitating its evaluation after introducing puta-
tive oncogenes.
hCdt1 and hCdc6 were expressed, separately, in the U2OS cells
by recombinant retrovirus infection. After successful infection
confirmation (Supplementary Fig. S2B), cells were collected for
flow cytometry to examine rereplication. Analysis revealed an
increase in the S-phase fraction and in the cells with a DNA content
>4n (Supplementary Fig. S2C). These findings suggest an S-phase
arrest with partially replicated DNA and some degree of rere-
plication without mitosis. Inability to enter mitosis was confirmed
with induction of the Tyr15-phosphorylated, inactive form of
the key mitosis-promoting kinase cdc2 (ref. 30; Supplementary
Fig. S2C). The degree of rereplication was not as high as previously
reported, probably because p53, which is wild-type in U2OS,
protects the cells from extensive rereplication (7). To test whether
these events led to DNA damage checkpoint activation, we
measured the levels of gH2AX, Chk2-pT68, and pS15-p53. Indeed,
their protein expression levels were higher compared with the
mock-infected cells (Supplementary Fig. S2B). Similar results were
observed in MCF-7 human breast cancer cells transfected with
hCdt1 and hCdc6 expressing vectors, separately or together
(Supplementary Fig. S3). Because ATM is activated not only by
DSBs but also by topological changes in chromatin structure (31),
the checkpoint components could well be activated in such an
alternative manner. To test the latter, pulsed-field gel electropho-
resis was done in the infected cells. Damaged DNA was evident in
both cases (Supplementary Fig. S2B), suggesting that rereplication
leads to replication fork collapse and DSB formation, which
eventually activate the DNA damage checkpoint.
Prolonged hCdt1 overexpression leads to a more aggressive
phenotype, bypassing the antitumor barriers of accelerated
senescence and apoptosis. The link between DDR activation and
Figure 2. hCdt1 and hCdc6 are frequently amplified in lung cancer. A, differential PCR, RT-PCR, and immunoblotting indicating hCdt1 and hCdc6 amplification
and overexpression. NE, normal expression; OE, overexpression; N, normal tissue; T, tumor tissue. B, the fold of hCdc6 and hCdt1 gene amplification and mRNA
increase observed in the corresponding cases. C, chromosome 17 CISH analysis with a c-erb2 probe in cases with hCdc6 gene amplification and in the HeLa cell line.
Differential PCR in embedded picture shows absence of c-erb2 amplification. D, CGH analysis in representative cases of lung cancer and their corresponding normal
tissue. Only the chromosomes of interest are presented. Red line, chromosomal loss; green line, chromosomal gain; n, number of cells analyzed.
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tumorigenesis (2–4, 32) implies that continuous DNA damage
checkpoint activation could lead to selective suppression of the
DDR-induced antitumor barriers, by inactivating mutations,
resulting in genomic instability and tumor progression.
To examine whether prolonged expression of RLFs could create
such a sequence of events, we developed an inducible hCdt1-U2OS
cellular system in which hCdt1 was expressed by addition of
doxycycline. We chose hCdt1 to generate the Tet-ON system,
because ectopic expression of hCdt1 is more potent in inducing
rereplication than that of hCdc6 (7) and because the expression of
endogenous hCdt1 is tightly regulated in vivo (24). The expression
levels of hCdt1 increased 4- to 5-fold, upon doxycycline induction
(Supplementary Fig. S4), a ratio similar to that found in dysplastic
and cancerous samples when compared with normal tissue or
hyperplasia (Supplementary Fig. S1A ; ref. 9). The degree of
overexpression achieved mimics closer the clinical scenarios than
the 20- to 100-fold increase reported previously (7, 8), which is most
unlikely to occur in vivo .
The hCdt1 effects were monitored for 30 days. Within 24 h after
hCdt1 induction, the DNA damage checkpoint became activated,
as assessed by g-H2AX and Chk2-pT68 levels (Fig. 3A). Activa-
tion of the checkpoint was more prominent over the following
days (Fig. 3A). Two days after hCdt1 induction, the cells under-
went morphologic changes with flattening and enlargement of the
cytoplasm. By day 4, they adapted a clear senescence phenotype,
as shown by SA-h-gal activity (Fig. 3B). The percentage of sene-
scent cells increased over the days culminating at day 8 (Fig. 3C).
Additionally, promyelocytic leukemia (PML) bodies, whose number
and size increases in ras-senescent cells (33, 34), increased by
number and size in hCdt1-overexpressing cells, also (Fig. 3B
Figure 3. U2OS-TetON-hCdt1 cells with and without doxycycline (Dox) treatment, monitored in the first 10 d of the experiment. A, immunoblot analysis for hCdt1,
g-H2AX, and Chk2-pT68 expression (H2AX and Chk2, loading controls). B, SA-h-gal staining and immunofluorescence staining for PML and g-tubulin (arrows,
aggregates of centrosomes). C, columns, mean of cells with positive SA-h-gal staining, foci of PML bodies per cell, and centrosome amplification, respectively;
bars, SD.
Cancer Research
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and C). The increase of PML nuclear bodies also indicates that
DNA damage occurs because they are associated with DNA les-
ions and repair (35, 36). Between days 8 and 15, an escalation
in apoptosis was denoted, as assessed by fluorescence-activated
cell sorting (FACS) and TUNEL assays, and accompanied by a
small decrease in the senescent-cell population (Supplementary
Fig. S4B). ATM-siRNA transfection of the induced cells resulted
in almost complete abrogation of senescence and apoptosis (Sup-
plementary Fig. S4C). Given that the U2OS cells are null for
the senescence-linked proteins p16INK4A and p14ARF (37, 38), our
results extend, using a novel candidate oncogene, and corroborate
our concept of oncogene-induced DDR as an anticancer barrier
(2–4).
After induction, FACS analysis showed an increase in the S-phase
fraction and in number of cells with DNA content >4n (Supple-
mentary Fig. S4B). According to a model, delay in S-phase prog-
ression, accompanied by pRb pathway defects, could lead to
centrosome amplification (39). Because U2OS cells have the pRb
pathway defective, due to p16INK4A loss (20), and a normal
centrosome profile by default (18), we examined the above
hypothesis by staining the cells with g-tubulin to identify the
number of centrosomes. Untreated U2OS-hCdt1 cells carried one
or two centrosomes per cell, as previously reported (18). After
24 h of hCdt1 induction, 40% of the cells presented centrosome
abnormalities. At day 4, f90% of the cells harbored an abnormal
centrosomal profile (structural and/or numerical aberrations,
excess pericentriolar material), which by days 8 and 10 was
present in almost all cells (Fig. 3B and C). Given the dominant role
of centrosomes in chromosome segregation (39), these results
suggest that deregulated hCdt1 expression, in addition to
recombination-prone rereplicated DNA, could create an environ-
ment permissive for chromosomal instability also due to centro-
some amplification.
Between days 10 and 15, the population of senescent and
apoptotic cells, as assessed by SA-h-gal, FACS, and TUNEL assays,
gradually decreased, and around days 25 to 30 exhibited the lowest
values (Supplementary Fig. S5). Monitoring the growth properties
of the hCdt1-induced cells, we observed, between days 6 to 15, a
growth and BrdUrd incorporation retardation, which coincide with
the senescence and apoptosis events described above (Supplemen-
tary Fig. S5A and B). Beyond this latter time point, BrdUrd
incorporation increased and cells started to grow at a higher rate
than the hCdt1 noninduced cells (Supplementary Fig. S5A and B).
Moreover, such emerging ‘‘adapted’’ cells showed nuclear atypia
characterized by micronuclei, lobulated nuclei, and nucleoplasmic
bridges (Fig. 4A and B). The noninduced cells did not show
Figure 4. Prolonged overexpression of hCdt1 induces genomic instability. A, micronuclei (arrows in A–C ) and lobulated nuclei (arrowheads in D–G ) in
U2OS-TetON-hCdt1 cells after 15 d of continuous hCdt1 induction. B, DNA content analysis, as assessed by Feulgen staining, in the induced U2OS-TetON-hCdt1
cellular system showing a gradual shift to polyploidy (>4C). C, images with representative morphologic characteristics, in noninduced and after prolonged (>15 d)
hCdt1 induction, of U2OS-TetON-hCdt1 cells, after g-tubulin immunofluorescence and 4¶,6-diamidino-2-phenylindole (DAPI ) staining (magnification, 610). Day 0,
control U2OS-TetON-hCdt1 cells, free of doxycycline, harbor one or two centrosomes per cell (arrows ) and normal bipolar mitoses (arrowhead ). Day 20 (20d ),
nucleoplasmic bridges (arrowhead). The two anaphasic nuclei are abnormally segregated because (see the corresponding g-tubulin and merged photos) three
centrosomes are visible next to the one anaphasic nucleus, whereas the other harbors only one centrosome. Next to them, a cell with two centrosomes (merged, arrow ).
Day 25 (25d ), a large cell with four prominent centrosomes (arrow ) and centriolar material forming a ‘‘beaded necklace’’ around the nucleus (arrowhead). Day 30 (30d ),
aberrant tetrapolar mitosis characterized by centrosome aggregates (arrowhead ) in a ring formation. Semicondensed chromatin does not manage to locate in the
middle of the central spindle (arrow ). D, mutual exclusive staining of Ki-67 (arrow ) and SA-h-gal (arrowhead) in U2OS-TetON-hCdt1 doxycycline-positive cells. Cells of
smaller size Ki-67–positive are also observed (magnification, 400).
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such alterations, excluding the possibility that these features
were due to cell culture propagation. Additionally, compared with
control noninduced cells, which displayed normal bipolar mitoses
(Fig. 4C), 10% to 13% of the induced cells exhibited after day 20
aberrant mitoses, characterized mainly by multipolarity (Fig. 4C).
These nuclear features are indicative of chromosomal instability
and are consistent with the ability of these cells to bypass the
DNA damage checkpoint (40, 41). Simultaneously, in comparison
with the noninduced cells, the DNA content histograms of the
hCdt1-induced cells, as assessed by Feulgen staining, exhibited
a rightward shift, from hypo/triploid values (2c–6c), at day 0 (21),
to values larger than 4c, after day 20 (Fig. 4B). A significant pro-
portion of cells contained DNA between 4c and 6c, with four
and six prominent centrosomes (Fig. 4B and C), respectively.
These results are indicative of S- and M-phase uncoupling lead-
ing to polyploidy, due to endoreduplication (42). Depending on
the cell cycle checkpoint(s) status and the apoptotic machinery
integrity, these cells will either die by mitotic catastrophe or
survive, dividing asymmetrically and giving rise to aneuploid
offsprings (42). The polyploid population, in our experimental
setting, emerged mainly when the antitumor barriers of apoptosis
and senescence were suppressed (Fig. 4B), contained increased
number of centrosomes, and stained positive for Ki-67 (Fig. 4D),
strongly suggesting that such cells follow the aneuploidy route.
Supporting the above, the levels of p53, the downstream effector
of the DDR pathway, showed a stepwise reduction after day 10,
despite expression of hCdt1 and g-H2AX (Fig. 5A ; Supplementary
Fig. S6).
According to a report, genotoxic insult–generated polyploidy
probably represents an important recombination repair response
(43). hCdt1-induced genomic recombination could take place
between homologous regions favored by the presence of rerepli-
cated DNA (7). Because rereplicated DNA produces DNA damage
(Supplementary Fig. S2B), we presumed that cells possessing
rereplicated DNA above a critical threshold should be ‘‘neutralized’’
by either senescence or apoptosis, whereas cells with rereplicated
elements below a critical threshold would be prone to recombina-
tion processes leading to genomic instability. These events would
favor the selection of cells resistant to hCdt1-induced apoptosis or
senescence. To examine the hypothesis that genomic instability is
induced by deregulated hCdt1, we did a SNP oligonucleotide
microarray analysis of the DNA extracted at days, 17, 30, and 60
against the 0 day extracted (Fig. 5B ; Supplementary Fig. S7). To
exclude the possibility of a cell culture effect, the DNA of the
noninduced cells from the same time points was also examined,
showing no alterations (data not shown). SNP oligonucleotide
Figure 5. Selection of more aggressive clones resistant to hCdt1-induced
apoptosis or senescence. A, immunoblot analysis for hCdt1, gH2AX, and
p53 expression at the corresponding time points. Actin, loading control.
B, genomic alterations after doxycycline treatment. The majority includes
fragile sites and important genes, whereas regions near centromeres are
also noticed. C, average of two similar independent experiments showing
the invasive potential of U2OS-hCdt1 cells overexpressing hCdt1 for 30 d.
Cancer Research
Cancer Res 2007; 67: (22). November 15, 2007 10906 www.aacrjournals.org
microarray analysis showed gradual increase in genomic alter-
ations, mainly gains, in an additive manner, ranging from 37 kb to
1.9 Mb (Fig. 5B ; Supplementary Fig. S7). Fragile sites, areas of the
genome prone to breaks and recombinations, were more frequently
affected (38% of all affected sites; Fig. 5B ; refs. 32, 44, 45), supporting
the notion of genomic reformation/recombination proposed earlier.
Among impaired chromosomal regions was 7p22.3 , which contains
part of the mitotic arrest deficient-like 1 (MAD1L1) gene (Fig. 5B).
MAD1L1 is essential for the mitotic spindle assembly checkpoint
that monitors chromosomal segregation fidelity, guarding against
the emergence of aneuploidy (46). Alteration at this specific
chromosomal area could perturb the normal function of MAD1L1 ,
affecting the mitotic checkpoint participating in the increased
aneuploidy observed after day 15 (Fig. 5B). Another gene possibly
affected is GAS6 (growth arrest–specific gene 6 ; 13q34 ; Fig. 5B).
Overexpression of GAS6 and its receptor tyrosine kinase Axl has
been associated with various carcinomas (47) and could contribute
to the aggressiveness of the arisen clone.
To investigate whether the acquired genomic alterations resulted
in a more aggressive behavior, we examined the invasive properties
of the evolved hCdt1 clones. Invasion and metastasis are the
hallmarks distinguishing malignancy from benign conditions. To
this end, an invasion assay was done between the induced and
noninduced at day 30. The former cells possessed a significantly
more potent invasion potential compared with the latter ones,
supporting the notion that genomic instability fuels premalignant
and malignant cells with mutations that promote their selective
advantage (ref. 48; Fig. 5C).
Figure 6. A, stable expression of hCdt1 and hCdc6 in papilloma P1 leads to cellular transformation. Black arrowheads, nucleoplasmic bridges. B, double
immunofluorescence analysis for cytokeratin (anticytokeratin, rabbit polyclonal, A0575, DAKO) and vimentin [antivimentin, mouse monoclonal (clone V9), isotype:
IgG1, n, DAKO] in P1-hCdc6 and the corresponding mock cells. Similar results were found in P1-hCdt1 cells (data not shown). C, tumorigenicity assay of
P1-pBabe-hCdt1 and P1-pBIB-hCdc6 cells and their corresponding mock cells in SCID mice. D, model showing that licensing factor deregulation, via replication stress,
exerts pressure on the DDR machinery, which eventually collapses, leading to genomic instability and clonal expansion of cells.
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Stable hCdt1 and hCdc6 expression in papilloma-premalig-
nant cells leads to cellular transformation. The hCdt1 and
hCdc6 role in early stages of carcinogenesis was further addressed
by examining their stable overexpression effects in the mouse
papilloma P1 cells. P1 are papilloma lines isolated from 7,12-
dimethylbenz(a)anthracene (DMBA)/12-O-tetradecanoylphorbol-
13-acetate (TPA)–treated spretus  CBA F1 mice (49). Generally,
they are nontumorigenic when injected s.c. into nude mice,
although occasionally at the injection sites either benign cysts
or well-differentiated tumors are seen (49). In vitro P1 cells have
a typical epithelial morphology being cuboidal in shape, with
a cobblestone pattern of growth (Fig. 6A). At the molecular level,
they posses a 2:1 mutant to wild-type H-ras alleles, due to a
chromosome 7 trisomy (49). The nontumorigenic nature of these
cells renders them as an appropriate premalignant epithelial
cellular system to study the transformation potential of putative
oncogenes.
The high Cdt1 and Cdc6 sequence homology between human
and mouse, respectively, and the reported ability of the human
Cdt1 and Cdc6 to function within the mouse environment (8), led
us to human retroviral constructs infection of P1 cells. During the
course of selection, the P1 cells started to acquire a spindle-
fibroblastoid morphology that was evident in both subconfluent
and confluent cell culture conditions while mock cells retained
their epithelial morphology (Fig. 6A). Certain morphologic features
observed in the activated U2OS-TetON-hCdt1 system, such as
nucleoplasmic bridges and micronuclei (Fig. 6A), which are
indicative of DNA misrepair, chromosome rearrangement, and
generally genomic instability (40), were present in the P1-hCdt1
and P1-hCdc6 as well. After 2 weeks of selections, clones were
picked up and propagated, and hCdt1 and hCdc6 expression was
confirmed (data not shown). Interestingly, the clones, in both cases,
had a uniform spindle appearance highly reminiscent of the
spindle-fibroblastoid morphology of the cell lines A5 and CarB,
which represent the most aggressive cellular type of the mouse skin
model (49). In agreement, the immunofluorescent evaluation of cell
intermediate filament status revealed a shift from a keratin-rich
network in the parental P1 and mock cells to a vimentin-rich
network in the P1-hCdt1 and P1-hCdc6 cells, indicative of an
epithelial to mesenchymal transition of the clones, also seen in A5
and CarB cell lines (Fig. 6B ; ref. 50).
To examine the P1-hCdt1 and P1-hCdc6 tumorigenicity, we
injected them s.c. at two sites on the one side of the abdominal
region of SCID mice, whereas, on the other side mock cells were
injected as controls. Within a period of 2 to 3 weeks, all P1-hCdt1
and P1-hCdc6 injected sites gave rise to tumors (20 of 20, 100%)
whereas the P1 mock cells gave tumors only in 1 of 20 sites (5%;
Fig. 6C).
Altogether, our results support the oncogenic potential of over-
expressed hCdt1 and hCdc6 from the earliest stages of
carcinogenesis. This is achieved by rereplication and generation
of DSBs. Initially, these events activate the antitumor barriers of
senescence and apoptosis but eventually are bypassed by the
continuous hCdt1 and hCdc6 stimulus, which induce genomic
instability favoring clonal expansion of cells with more aggressive
properties (Fig. 6D).
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